Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential

Bristol-Myers Squibb and AstraZeneca will need to design a precedent-setting cardiovascular outcomes study for saxagliptin before the drug will be approved by the agency

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet